journey vinyl frontiers

• Phono Preamps
• Analog Accessories
• Record Care
• Disc Players
• Network Audio Players
• Portable Music Players
• Integrated Amps
• Surround Sound
• Floor-Standing Speakers
• Bookshelf Speakers
• Center Channel
• Powered/Wireless Speakers
• Headphone Amps
• Power Conditioning
• Vibration Control
• Vacuum Tubes

• Pre-Order Vinyl
• Closeout Vinyl
• Out-Of-Print Vinyl
• New Digital
• Pre-Order Digital
• Closeout Digital
• Out-Of-Print Digital
• Mobile Fidelity
• Speakers Corner
• Analogue Productions
• Warner Bros.
• Female Vocal

• Amplification
• Accessories
• Out of Print
• Hardware Sales
• Accessory Sales

Brand: LEGACY RECORDS

Journey - frontiers: 40th anniversary remastered (180g vinyl lp + 7").

• Create New Wish List

Be alerted when Journey - Frontiers: 40th Anniversary Remastered (180g Vinyl LP + 7") is back in stock

• Track Listing
• Reviews ( 0 )

Journey's 1983 Album Frontiers Has Been Remastered for Its 40th Anniversary on 180g LP. Also Includes a Bonus 7" With 4 Additional Tracks.

On October 27 Legacy Recordings will release the 40 th anniversary of Journey’s 1983 classic album, Frontiers .  Newly remastered this 180g vinyl contains the smash hit “Faithfully” and will also include a bonus 7” that has 4 additional tracks. Two of the tracks “Only The Young” and “Ask The Lonely” were originally intended for the album but left off due to vinyl time constraints. “Only The Young” ended up on the Vision Quest Soundtrack while “Ask The Lonely” appeared on the Two of A Kind soundtrack. The bonus 7” also includes remixes of “Only The Young” and “Separate Ways (Worlds Apart)” by Steve Perry & Bryce Miller.  The remix of Separate Ways was most recently featured on the NETFLIX series Stranger Things, Season 4.

1. Separate Ways (Worlds Apart)

2. Send Her My Love

3. Chain Reaction

4. After The Fall

5. Faithfully

1. Edge Of The Blade

2. Troubled Child

3. Back Talk

4. Frontiers

1. Only The Young (Steve Perry & Bryce Miller Remix)

2. Separate Ways (Worlds Apart) (Steve Perry & Bryce Mille Extended Remix)

1. Only The Young

2. Ask The Lonely

No interest if paid in full in 12 months

Check out the newest Music Direct catalog

Please allow 24-48 hours for a response.

Help & Technical Support

Music direct - free shipping policy.

Place a qualifying order over $49* and receive FREE DOMESTIC GROUND SHIPPING. When your order subtotal reaches $49 in the shopping cart the shipping charge for associated qualifying items will automatically be adjusted on your order. If you continue to see a shipping charge on your order, please check the exclusions listed below.

*Ground shipping to the 48 contiguous states only (FPO/APO excluded). **Orders must be at least $49, before tax, to qualify. This offer also excludes Oppo, demos, closeouts/sale items and freight shipped items. This offer cannot be applied to previously placed orders. Music Direct reserves the right to select the carrier and ship method within the terms of this offer. Music Direct reserves the right to change the terms of this promotion or discontinue this offer at any time. This offer is not included on any shipments to FPO/APO addresses. Music Direct will contact you with shipping charges for these addresses. Customers can choose an alternative expedited shipping method but it will not qualify for this free shipping offer. Music Direct will not charge additional shipping for any back orders items. Orders will be held to ship all back ordered items together when they are all received in stock.

Please Note: Orders that are less than $125 are not guaranteed to ship via FedEx. The ground shipping method used will be determined at Music Direct's discretion. Average ground delivery time ranges from 7-14 business days. Music Direct does not guarantee delivery within that specified time period.

YOUR 60-DAY SATISFACTION GUARANTEE

We strive for 100% customer satisfaction with every order and back it up with our 60-Day Satisfaction Guarantee. Should you have an issue of any kind, rest assured we're here to make it right! We stand behind every product we sell and offer free live support if you need assistance setting-up, troubleshooting, or maximizing your purchase. We also have a variety of resources available to customers including:

• Access to our expert sales staff at 312-433-0200
• Email customer support
• Product Q&As

In the event you receive a defective or damaged product you can exchange or return items within 60 days. You can review our complete return policy here .

•   My Account
• New Arrivals
• Coming Soon
• Colored Vinyl
• Picture Disc
• Shop All Vinyl
• Shop All Digital
• Reel to Reel Tape
• Alternative
• Country Bluegrass
• Integrated Amplifiers
• Phono Preamps
• Analog to Digital Converters
• Digital to Analog Converters
• Music Hall CD Players
• Musical Fidelity CD Players
• Cayin CD Players
• AKG Headphones
• Grado Headphones
• Stax Headphones
• Audeze Headphones
• Audioquest Headphones
• Headphone Amps
• Epos Loudspeakers
• Edifier Loudspeakers
• Airpulse Loudspeakers
• Graham Engineering Tonearms
• Clearaudio Tonearms
• VPI Tonearms
• Clearaudio Turntables
• Music Hall Turntables
• Musical Fidelity
• Pro-ject Turntables
• Rock n Rolla Turntables
• Shinola Turntables
• VPI Turntables
• Sota Turntables
• Grado Cartridges
• Lyra Cartridges
• Koetsu Cartridges
• Audio-Technica Cartridges
• Clearaudio Cartridges
• Hana Cartridges
• Air Tight Cartridges
• Soundsmith Cartridges
• Sumiko Cartridges
• Van Den Hul Cartridges
• Ortofon Cartridges
• Kiseki Cartridges
• Phasemation Cartridges
• All Phono Cartridges
• Headshell Weights
• Headshell Leads
• Cartridge Accessories
• Tonearm Accessories
• Turntable Belts
• Turntable Dust Covers
• Turntable Levels
• Turntable Set-Up
• Turntable Speed Control
• Turntable Tweaks & Upgrades
• Vibration Isolation
• Replacement Headphone Ear Pads
• Headphone Stands
• Headphone Cables
• Noise Filtering
• Contact Cleaners/Enhancers
• Power Conditioning
• Power Cables & Outlets
• Speaker Accessories
• LP Flatteners
• Magnetic Tape Preservative
• Record Brushes
• Record Clamps
• Record Cleaner Accessories
• Record Cleaning Fluids
• Record Frames
• Record Mats
• Record Sleeves
• Test & Set-Up LPs
• Single 7" 45 Adaptors
• CD/DVD Cleaning
• Test & Set-Up CDs
• Sound Enhancement
• Vacuum Tubes
• Books & Magazines
• Nitty Gritty Record Cleaners
• VPI Record Cleaners
• Spin Clean Record Cleaners
• Music Hall Record Cleaners
• Audio Desk Systeme Record Cleaners
• Clearaudio Record Cleaners
• Sota Record Cleaners
• KirmussAudio
• Orbitrac 3 Record Cleaners
• Pro-Ject Record Cleaners
• Shop All Record Cleaning Machines
• Tonearm Cables
• Digital Cables
• Speaker Cables

Journey Frontiers (40th Anniversary Edition) 180g LP & 7" Vinyl

• Create New Wish List
• Description

40th Anniversary Edition 180g Vinyl LP! Remastered for Vinyl from the Original Stereo Master Tapes! Includes a Bonus 7"!

For its 40th anniversary, Journey's classic 1983 album Frontiers is newly remastered from the original stereo master tapes and pressed on 180g vinyl.

Certified 6x Platinum, the package contains the hits "Separate Ways (Worlds Apart)," "Faithfully" and "Send Her My Love" plus a bonus 7" featuring new remixes of "Only the Young" and "Separate Ways (Worlds Apart)" by Steve Perry and Bryce Miller along with the original single versions of "Only the Young" and "Ask the Lonely" that were left of the original vinyl release due to time constraints. "Only the Young" ended up on the Vision Quest soundtrack while "Ask the Lonely" appeared on the Two of a Kind soundtrack.

The 7" plays at 33 1/3 RPM.

• 40th Anniversary Edition
• 180g Vinyl LP
• 2023 Vinyl Produced by Steve Perry & John Jackson
• Remastered for Vinyl from the Original Stereo Master Tapes by Adam Ayan at Gateway Studios, Portland, ME
• Lacquer Cut by Chris Bellman at Bernie Grundman Mastering, Hollywood, CA
• Bonus 7" with 2 New Remixes of "Only the Young" & "Separate Ways (Worlds Apart)" + Original Single Versions of "Only the Young" & "Ask the Lonely"
• 7" Vinyl Plays at 33rpm
• Separate Ways (Worlds Apart)
• Send Her My Love
• Chain Reaction
• After the Fall
• Edge of the Blade
• Troubled Child

Bonus 7" Vinyl (Plays at 33 1/3 rpm)

• Only the Young (Steve Perry & Bryce Miller Remix)
• Separate Ways (Worlds Apart) [Steve Perry & Bryce Mille Extended Remix]
• Only the Young
• Ask the Lonely

Customers Also Like

Journey Escape (40th Anniversary Edition) 180g LP

Availability: Backordered

Blue Oyster Cult Agents of Fortune Live 2016 LP

Rush Permanent Waves Deluxe Edition 180g 3LP

Availability: In Stock

Rush Signals (40th Anniversary) DMM Half-Speed Mastered 180g LP, CD, Blu-Ray Audio & 4 45rpm 7" Vinyl Singles Box Set

Rush Hemispheres 180g 3LP

Your trusted worldwide source for music, equipment and accessories since 1989.

Call Customer Service 1-800-782-3472

We Ship Everything with a little extra care

We make sure your order gets delivered to you in perfect condition. Each shipment is hand-packaged by our team with the utmost care and attention to detail.

Sign-Up Today for Exclusive Sales & Promotions

FREE SHIPPING ON DOMESTIC ORDERS OVER $79.99

QUICK LINKS

• SELECTION OF THE MONTH
• HOLIDAY RECORDS
• NEW ARRIVALS
• REFUND POLICY
• Terms of Service
• MATT SORUM LOVES VINYL

CONNECT WITH US

• (212) 301-0560

GET ON THE LIST!

Sign up for our newsletter for new releases, reissues, and exclusive vinyl.

By submitting this form, you are consenting to receive marketing emails from: Experience Vinyl. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact.

Curated by musicians and music lovers like Rock ‘n’ Roll Hall of Famer Matt Sorum, Experience Vinyl is the vinyl club without the commitment. Like other clubs, every month we offer a limited edition pressing. Like other clubs, each album is chosen by its impact on us and the music world.

Unlike other clubs, you have zero obligation to buy it. It’s your music, your money, your choice. Get limited-run, collector’s edition pressings of only what you love.

JOURNEY - FRONTIERS 40TH ANNIVERSARY Vinyl LP

• Open media 1 in modal

Couldn't load pickup availability

40th anniversary edition of this classic album on 180g vinyl, remastered from the original stereo master tapes. Certified 6x Platinum. Includes the hits "Separate Ways (Worlds Apart)", "Faithfully" and "Send Her My Love" plus a bonus 7" featuring new remixes of "Only The Young" and "Separate Ways (Worlds Apart)" by Steve Perry and Bryce Miller along with the original single versions of "Only The Young" and "Ask The Lonely" that were left of the original vinyl release due to time constraints. The 7" plays at 33 1/3 RPM.

1 Separate Ways (Worlds Apart)

2 Send Her My Love

3 Chain Reaction

4 After the Fall

5 Faithfully

1 Edge of the Blade

2 Troubled Child

3 Back Talk

4 Frontiers

1 Only the Young (Steve Perry & Bryce Miller Remix)

2 Separate Ways (Worlds Apart) (Steve Perry & Bryce Mille Extended Remix)

1 Only the Young

2 Ask the Lonely

Label: Sony Legacy

• Choosing a selection results in a full page refresh.

• Female Vocalists
• Christmas/Holiday
• more music genres

• Vinyl Records
• Vinyl LP Box Sets - New & Preowned
• Vinyl Box Sets

Journey Frontiers (40Th Anniversary Remastered)

40th anniversary edition of this classic album. 180-gram audiophile vinyl, remastered from the original stereo master tapes. Certified 6x Platinum. Includes the hits “Separate Ways (Worlds Apart)”, “Faithfully” and “Send Her My Love” plus a bonus 7” featuring new remixes of “Only The Young” and “Separate Ways (Worlds Apart)” by Steve Perry and Bryce Miller along with the original single versions of “Only The Young” and “Ask The Lonely” that were left of the original vinyl release due to time constraints. The 7” plays at 33 1/3 RPM.

• 1. Separate Ways (Worlds Apart)
• 2. Send Her My Love
• 3. Chain Reaction
• 4. After the Fall
• 5. Faithfully
• 6. Edge of the Blade
• 7. Troubled Child
• 8. Back Talk
• 9. Frontiers
• 10. Rubicon
• 11. Only the Young
• 12. Separate Ways (Worlds Apart) - Journey, Steve Perry
• 13. Only the Young
• 14. Ask the Lonely

Knocked Loose — A Tear In The Fabric of Life Pure Noise Records / May 10, 2024

Griff — vertigo (sea blue bio) warner records / july 19, 2024, tody castillo — tody castillo strolling bones records / june 21, 2024, junko ohashi — magical ohashi junko no sekai 3 [2xlp] lawson ent / august 9, 2024, deep purple — =1 [2xlp] earmusic / july 19, 2024, mötley crüe — dogs of war (picture disc) big machine / june 14, 2024, freddie mckay — creation vp records / may 31, 2024.

Install our app to receive notifications when new upcoming releases are added.

Recommended equipment and accessories

Denon DP-400

AudioTechnica AT-SB727 Sound Burger

Nobsound Little Bear T7 Tube Preamp

Boundless Audio Record Cleaner Kit

Cork Turntable Mat

Featured upcoming vinyl.

Zachary Cale Next Year's Ghost

Lany I Really Really Hope So

Fat White Family Forgiveness Is Yours

Voidwomb Spiritual Apotheosis

Beth Gibbons Lives Outgrown

Cigarettes After Sex X's (Deluxe)

Ponyland Harebrains

Einsturzende Neubauten Rampen apm: alien pop music [2xLP]

Amiensus Reclamation

Crowded House Gravity Stairs

Sebastian Bach Child Within The Man [2xLP]

Porter Robinson SMILE! :D (Amazon Exclusive)

Meghan Trainor Timeless

Rifflord 39 Serpent Power

Featured posts.

Notable vinyl releases out this Friday - 26 April (2024)

Notable vinyl releases out this Friday - 19 April (2024)

Notable vinyl releases out this Friday - 12 April (2024)

Purveyors of Vinyl since 1962

FREE SHIPPING when you spend €40

Record Store Day

ACCESSORIES

The Vinyl Brew

Gift Vouchers

T-Shirt/Apparel

Collectables

Your cart is empty

Frontiers (40th Anniversary) - Journey [VINYL]

Description.

Disc 1 1. Seperate Ways (Worlds Apart) - Journey (5.26) 2. Send Her My Love - Journey (3.55) 3. Chain Reaction - Journey (4.20) 4. After the Fall - Journey (5.01) 5. Faithfully - Journey (4.26) 6. Edge of the Blade - Journey (4.30) 7. Troubled Child - Journey (4.29) 8. Back Talk - Journey (3.16) 9. Frontiers - Journey (4.09) 10. Rubicon - Journey (4.18)

Disc 2 1. Only the Young (Steve Perry & Bryce Miller Extended Remix) (Bonus Track) - Journey (3.35) 2. Separate Ways (Worlds Apart) [Steve Perry & Bryce Miller Extended Remix] (Bonus Track) - Journey (3.15) 3. Only the Young (Bonus Track) - Journey (4.17) 4. Ask the Lonely (Bonus Track) - Journey (3.54)

Production Info

This product is: in-stock

In-stock: 90% of orders are dispatched within 24 hours of purchase. Please see our shipping timetable here.

Out of stock:  Enter your email address on the product page and we will notify you once the title is back in stock.

Pre-Order:  will be dispatched upon the title release date.

Special Order:  will take up to 3 weeks to source and dispatch.

If your order contains multiple types of product (e.g: an 'in-stock' item and a 'pre-order' item), the entire order will be held for dispatch until the Pre-Order release date or the 3 week Special Order window has elapsed, whichever is longer.

Please note:  To avoid any unwanted delays, please order separately.

Free shipping

for orders of €/£40 or more.

Fast Order Dispatch time

Usually on the next day.

Professional Vinyl Packaging

for EVERY order.

Professional and Knowledgable

We are DJs and collectors.

Journey – Frontiers

Out of stock

Journey – Frontiers Label: Columbia Format: Vinyl, LP, Album Country: US Released: 1983 Genre: Rock Style: AOR, Classic Rock, Arena Rock

Sleeve Rating: Very Good (VG)

Media rating: very good (vg).

Need help understanding Record Grading/Ratings?  Click the link below to learn more: Record Grading 101 : Click Here

*Sleeve images are representative only and may differ from stock items.

Other Vinyl You May Dig...

Jimi Hendrix Accompanied By Mitch Mitchell And Noel Redding – More Experience (Volume Two)

The Raiders – Indian Reservation

Vinegar Joe – Vinegar Joe

The Next Morning – The Next Morning

Stay up to date.

Be the first to know when new vinyl is added to the store.  Albums are added weekly.

CASE REPORT article

Case report: from negative to positive: a remarkable journey of er, pr and her2 status in a patient with metastatic breast cancer.

• 1 Department of Oncology, Jiujiang University Affiliated Hospital, Jiujiang, Jiangxi, China
• 2 Department of Ultrasonic Diagnosis, Jiujiang University Affiliated Hospital, Jiujiang, Jiangxi, China

Breast cancer is the most common malignant tumor in women, posing a serious threat to women’s health. HER2 has been identified as a key oncogene and prognostic factor in breast cancer. Recent studies have reported inconsistencies in ER, PR, and/or HER2 expression between primary breast tumors and metastatic lesions. Rarely is it reported that all three biomarkers experience conversion. In this report, we present the case of a female patient with relapsed and metastatic breast cancer, whose histology transformed from initially triple-negative to Luminal-B type (HER2 positive) (i.e., ER, PR, and HER2 positive). She underwent systematic chemotherapy, targeted therapy, and cranial radiotherapy, which was followed by maintenance treatment with targeted and endocrine therapy. Currently, she has been in nearly complete remission (nCR) for more than 12 months. For recurrent and metastatic breast cancer, it is necessary to perform the second biopsy for metastases, which would contribute to precision treatment and prognosis improvement.

Introduction

According to the latest National Cancer Report, breast cancer is the most common malignant tumor and the second leading cause of cancer mortality in Chinese females ( 1 ). The therapeutic strategies for newly-diagnosed breast cancer include surgery, chemotherapy, radiotherapy, targeted therapy, and endocrine therapy. The choice of treatment depends on the stage of TNM, pathology, molecular types, and physical conditions ( 2 ). For relapsed and metastatic breast cancer, the treatment strategy is primarily based on the original pathological and molecular types of the cancer ( 2 ). Recently, several retrospective studies have reported inconsistent biomarkers, i.e. estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2), between the primary lesions and metastases of breast cancer ( 3 – 6 ). The majority of the discordance occurred only one or two of ER, PR and HER2 status. It is rarely reported that all three biomarkers simultaneously changed between primary lesion and recurrent & metastases. In this report, we present a case of a female patient with stage IIIA breast cancer who experienced a transition from initial triple-negative to Luminal-B type (HER2 positive) after recurrence and metastasis. As a result, she received anti-HER2 therapy plus chemotherapy and achieved nearly complete remission (nCR).

Case report

On March 2, 2018, a 31-year-old woman complained of a palpable mass in the left breast for more than 2 months. The serum levels of CEA and CA153 were 22.5ng/ml and 46.8U/ml, respectively. Then she was diagnosed with left breast cancer and underwent a modified radical resection at Jiujiang University Affiliated Hospital. Postoperative pathology revealed invasive ductal carcinoma of the left breast, non-specific type, with left axillary lymph nodes metastasis (5/23). Immunohistochemical examinations showed ER (-), PR (-), HER2 (-), and Ki-67 (80% +), indicating triple-negative type breast cancer ( Figure 1 ). Because the patient possessed a certain degree of medical knowledge, she required further examination of HER2 by fluorescence in situ hybridization (FISH). The negative status of HER2 was typically confirmed by FISH.

Figure 1 The changes of biomarkers between newly-diagnosed and relapsed biopsies. (A–D) Negative expression of ER, PR, and HER-2. (E–H) Positive expression of ER, PR, and HER-2.

The stage of TNM was pT2N2aM0, stage IIIA. Due to the high risk of relapse (≥4 axillary lymph node positive), the patient received adjuvant chemotherapy since April 4, 2018. Specifically, the combined regimen consisted of epriubicin and cyclophosphamide (EC) for 4 cycles with 1 cycle every 3 weeks. Then, she was treated with albumin-bound paclitaxel (T) for 4 cycles per 3 weeks cycle. On Oct. 10, adjuvant radiotherapy was administered to the chest wall and regional lymph node drainage field, with 25 daily doses (fractions) of 2.0 Gy to a total dose of 50Gy over 5 weeks. The patient was followed up regularly and examined every 3 months during the first 2 years after surgery, including tumor markers, breast ultrasound, chest and abdominal CT, and brain MRI examinations. Sine the third year after operation, she received regular evaluation every 6 months. The patient was in good condition and no signs of tumor recurrence were found.

In December 2022, the patient complained of right upper abdominal discomfort, loss of appetite and occasional nausea. The patient was examined at our Hospital on December 22, 2022. The CEA level was 32.86ng/ml. The CA153 level was greater than 342.5ng/ml. Abdominal CT indicated multiple metastatic tumors of the liver ( Figure 2 ). On January 4, 2023, the brain magnetic resonance imaging (MRI) was performed. It found an abnormal signal in the right frontal nodule, suggesting metastasis. Cervical lymph node ultrasonography showed abnormal structural lymph nodes in the bilateral neck region II and left neck region V. The maximum diameter of lymph nodes was only 1.4 cm. Also, the physical examination showed no significantly palpable superficial lymph nodes. Thus, the patient received percutaneous color ultrasound-guided needle biopsy of liver biopsies on January 4, 2023. Pathological findings supported that the liver metastases were consistent with breast cancer. Immunohistochemistry results showed ER (70% +), PR (40% +), Ki-67 (40% +), as well as the positive expression of HER2 (2+). Furthermore, the positive status of HER2 was confirmed by FISH detection ( Figure 1 ). Finally, the patient was diagnosed with Luminal B type (HER2 positive), i.e. ER, PR, and HER2 positive. The patient received stereotactic radiotherapy (SRT) with DT50Gy/10F for the solid brain metastasis on January 8, 2023. Concurrently, the patient received the combined treatment of docetaxel(D), trastuzumab (H), and pertuzumab(P) (D-HP) for 6 cycles, with each cycle lasting 3 weeks, starting from January 11, 2023. The clinical efficacy was evaluated based on the Response Evaluation Criteria for Solid Tumors (RECIST1.1), including complete response (CR) and partial remission (PR). CR indicates that all lesions disappear completely, and all pathological lymph nodes reduce to normal size (short diameter < 1cm), lasting for more than 1 month. PR means that the total maximum diameter of all measurable lesions reduces by over 30%, lasting for more than 1 month. Nearly CR (nCR) refers to that the majority of all measurable lesions disappear, but only a few tiny residual foci remain.

Figure 2 The CT changes of different metastatic lesions from liver (A–D) .

After 3 cycles of treatment, the clinical efficacy showed partial remission (PR). After 6 cycles of treatments, the patient achieved complete remission (CR) of cervical metastatic lymph nodes and brain metastasis ( Figure 3 ). For liver metastases, the clinical efficacy showed partial remission (PR). Since May 21, 2023, the patient began to receive maintenance therapy, which included trastuzumab, leuprorelin, letrozole, and Abemaciclib (an inhibitor of CDK4/6). Currently, the patient is receiving regular maintenance therapy without any clear discomfort. In December 2023, the latest efficacy was evaluated, and the hepatic metastatic lesions almost disappeared, indicating nCR ( Figure 2 ). She has achieved progression-free survival (PFS) of over 12 months and the overall survival of 69 months up to now ( Figure 4 ). The patient still undergoes close follow-up and receives regular examination every 6 months.

Figure 3 Magnetic resonance imaging (MRI) examinations of right frontal lobe metastasis (red arrow). (A, D) The presence of solid brain metastasis (diameter of 1 cm). (B, E) and (C, G) The disappearance of brain metastasis.

Figure 4 Detailed time course of the patient's clinical course and therapeutic regimens.

Previously, it was believed that breast cancer was a static disease in terms of pathology. However, in-depth molecular studies have found that breast cancer should be considered as a spatially and temporally dynamic disease, i.e. that the heterogeneities exist in different sites between primary tumors and metastases, and different phases between initial diagnosis and recurrence ( 7 ). The phenomenon of heterogeneity between primary and metastatic lesions has attracted increasing attention from clinicians in the field of breast cancer. Timmer M et al. compared the status of ER, PR, and HER2 in primary tumors with brain metastases in 24 patients with breast cancer. They found that 25-37.5% of patients exhibited discordant receptor status between the primary tumor and brain lesions ( 4 ). Nishimura R et al. reported the changes in ER, PR, Ki-67, and HER2 status between primary and recurrent lesions in 97 patients with breast cancer. Following relapse, ER and PR decreased while Ki-67 increased. Subtype changes occurred in 24.7% of the patients ( 5 ). Lin M et al. compared the changes in HER2 status between primary tumors and paired recurrent/metastatic lesions in 1299 patients with breast cancer. The incidence of discordance was 28.5% (370/1299), indicating the conversion of primary-to-metastatic HER2 status ( 3 ). The results indicated that the heterogeneity between primary and metastatic lesions is an important clinical issue that cannot be ignored.

The underlying mechanisms have been partly ascribed to clonal evolutions, which contribute to genetic heterogeneity during malignant progression. Sprouffske K et al. faithfully mimicked the clonal evolution of metastasis process in the patient-derived tumor xenografts (PDX) from breast cancer. During the process of clonal selection, some subclones remain stable, some expand, and others vanish over time. Furthermore, clonal evolution leads to genetic heterogeneity and different clinical outcomes ( 8 ). A prospective analysis of circulating tumor DNA (ctDNA) was performed by next-generation sequencing (NGS) in 37 patients with HR-positive, HER2-negative breast cancer who were classified as secondary resistance. The occurrences of new mutations were 0% (0/9) for the chemotherapy group, 42.1% (8/19) for the CDK4/6 inhibitors plus endocrine treatment (CE group), and 36.3% (4/11) for the chemotherapy followed by CE group (p=0.024). The results strongly indicated that chemotherapy or CDK4/6 inhibitors may influence the change of clonal evolution among breast cancer patients ( 9 ). Liquid biopsy by Kujala J et al. detected 56.2 ± 7.2% of somatic variants present both in the matched primary tumor and metastatic sites from breast cancer patients. Apparently, liquid biopsy may identify novel driver variants and therapeutic targets absent from the tumor tissue DNA ( 10 ). In the clinical setting, ctDNA may be an ideal surrogate for longitudinal monitoring of genetic heterogeneity from breast cancer patients who can’t obtain tissue specimen ( 7 ). Another potential explanation may be attributed to that a second local lesion ( in situ or invasive) could have developed concomitantly with the primary DCIS or in the period between the primary tumor and recurrence, which could be a plausible explanation for the luminal metastases. Thus, it is necessary and important to follow-up the patients with breast cancer.

According to the studies, all the insistences occurred in only one or two of three receptors (ER, PR, and HER2 receptors) in breast cancer patients at the stages of initial diagnosis and recurrence & metastasis ( 3 – 5 ). However, the transition from triple-negative to ER, PR, and HER2 positive status was rarely observed. In our report, we present a case of a female patient newly diagnosed with triple-negative breast cancer, who experienced multiple metastases to the liver, brain, and cervical lymph nodes 57 months after the operation. A re-biopsy of the liver metastases revealed a conversion into ER, PR, and HER2 positive status. In this case, the liver was the optimal site available for re-biopsy. As a result, the patient received accurate detection and precision medicine. Encouragingly, the patient achieved nCR for all the metastases after systematic treatments. This re-confirmed the correct diagnosis after disease relapse and metastasis. In contrast, re-biopsy from brain metastasis is not easily available for breast cancer patients. In this clinical setting, liquid biopsy of ctDNA [including cerebrospinal fluid (CSF)] may be an alternative option for these types of patients ( 11 ).

Conclusions

The discrepancy in the biomarkers of ER, PR, and HER2 status presents a significant clinical challenge in patients with breast cancer, particularly between primary tumors and metastatic lesions. Simultaneous conversion of all three biomarkers is a rare occurrence during the disease progression of breast cancer. This study presents a case of a female patient with initial triple-negative breast cancer who transformed to ER, PR, and HER2-positive status after recurrence and metastasis. Consequently, she underwent systematic treatment, including chemotherapy, targeted therapy, cranial radiotherapy, and maintenance treatment. The patient achieved a promising complete response (nCR) for over 12 months up to now. The final results of CLEOPATRA study reported that mOS and 8-year OS rates were significantly higher in the D-HP group than that in was D-H (docetaxel-trastuzumab) group ( mOS : 57.1 vs . 40.8 months; 8-year OS rates : 37% vs . 23%) ( 12 ). Therefore, we have reasons to believe that the patient is likely to have an excellent outcome. This report highlights the necessity and importance of secondary biopsy in patients with breast cancer, which could significantly facilitate precise diagnosis and treatment.

Data availability statement

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding authors.

Ethics statement

The studies involving humans were approved by Ethic Committee of Jiujiang University Affiliated Hospital. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

Author contributions

JH: Investigation, Methodology, Writing – original draft. LL: Data curation, Formal analysis, Methodology, Writing – original draft. JD: Conceptualization, Software, Writing – review & editing.

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

1. Tao X, Li T, Gandomkar Z, Brennan PC, Reed WM. Incidence, mortality, survival, and disease burden of breast cancer in China compared to other developed countries. Asia Pac J Clin Oncol . (2023) 19:645–54. doi: 10.1111/ajco.13958

PubMed Abstract | CrossRef Full Text | Google Scholar

2. Loibl S, Poortmans P, Morrow M, Denkert C, Curigliano G. Breast cancer. Lancet . (2021) 397:1750–69. doi: 10.1016/S0140-6736(20)32381-3

3. Lin M, Luo T, Jin Y, Zhong X, Zheng D, Zeng C, et al. Her2-low heterogeneity between primary and paired recurrent/metastatic breast cancer: implications in treatment and prognosis. Cancer . (2023) 130:851–62. doi: 10.1002/cncr.35101

4. Timmer M, Werner JM, Rohn G, Ortmann M, Blau T, Cramer C, et al. Discordance and conversion rates of progesterone-, estrogen-, and her2/neu-receptor status in primary breast cancer and brain metastasis mainly triggered by hormone therapy. Anticancer Res . (2017) 37:4859–65. doi: 10.21873/anticanres.11894

5. Nishimura R, Osako T, Okumura Y, Tashima R, Toyozumi Y, Arima N. Changes in the er, pgr, her2, p53 and ki-67 biological markers between primary and recurrent breast cancer: discordance rates and prognosis. World J Surg Oncol . (2011) 9:131. doi: 10.1186/1477-7819-9-131

6. Pellas U, Bauer A, Baros IV, Fattorini C, Tot T. Her2-low metastases of her2-negative primary tumors: a single institution analysis of intertumoral and internodal heterogeneity in node-positive breast cancer. Front Oncol . (2023) 13:1167567. doi: 10.3389/fonc.2023.1167567

7. Kavan S, Kruse TA, Vogsen M, Hildebrandt MG, Thomassen M. Heterogeneity and tumor evolution reflected in liquid biopsy in metastatic breast cancer patients: a review. Cancer Metastasis Rev . (2022) 41:433–46. doi: 10.1007/s10555-022-10023-9

8. Sprouffske K, Kerr G, Li C, Prahallad A, Rebmann R, Waehle V, et al. Genetic heterogeneity and clonal evolution during metastasis in breast cancer patient-derived tumor xenograft models. Comput Struct Biotechnol J . (2020) 18:323–31. doi: 10.1016/j.csbj.2020.01.008

9. Decker T, Bichler M, Birtel A, Fischer G, Geiger K, Gaenger S, et al. Clonal evolution in patients with hormone receptor positive, her-2 negative breast cancer treated with chemotherapy or cdk4/6 inhibitors. Oncol Res Treat . (2022) 45:248–53. doi: 10.1159/000523758

10. Kujala J, Hartikainen JM, Tengstrom M, Sironen R, Auvinen P, Kosma VM, et al. Circulating cell-free dna reflects the clonal evolution of breast cancer tumors. Cancers (Basel) . (2022) 14:1332. doi: 10.3390/cancers14051332

11. Fitzpatrick A, Iravani M, Mills A, Vicente D, Alaguthurai T, Roxanis I, et al. Genomic profiling and pre-clinical modelling of breast cancer leptomeningeal metastasis reveals acquisition of a lobular-like phenotype. Nat Commun . (2023) 14:7408. doi: 10.1038/s41467-023-43242-x

12. Swain S, Miles D, Kim S, Im Y, Im S, Semiglazov V, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol . (2020) 21:519–30. doi: 10.1016/S1470-2045(19)30863-0

Keywords: breast cancer, ER, PR, HER2, transformation, negative, positive

Citation: Huang J, Liu L and Ding J (2024) Case report: From negative to positive: a remarkable journey of ER, PR and HER2 status in a patient with metastatic breast cancer. Front. Oncol. 14:1381541. doi: 10.3389/fonc.2024.1381541

Received: 03 February 2024; Accepted: 15 April 2024; Published: 26 April 2024.

Reviewed by:

Copyright © 2024 Huang, Liu and Ding. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Jianghua Ding, [email protected]

† These authors have contributed equally to this work

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Image Unavailable

• Sorry, this item is not available in
• Image not available
• To view this video download Flash Player

Similar items that may deliver to you quickly

Product details

• Is Discontinued By Manufacturer ‏ : ‎ No
• Package Dimensions ‏ : ‎ 12 x 12 x 0.01 inches; 8 ounces
• Manufacturer ‏ : ‎ columbia records
• Date First Available ‏ : ‎ August 15, 2007
• Label ‏ : ‎ columbia records
• ASIN ‏ : ‎ B000V4YZA6
• Number of discs ‏ : ‎ 1

Customer reviews

Customer Reviews, including Product Star Ratings help customers to learn more about the product and decide whether it is the right product for them.

To calculate the overall star rating and percentage breakdown by star, we don’t use a simple average. Instead, our system considers things like how recent a review is and if the reviewer bought the item on Amazon. It also analyzed reviews to verify trustworthiness.

Reviews with images

• Sort reviews by Top reviews Most recent Top reviews

Top reviews from the United States

There was a problem filtering reviews right now. please try again later..

Top reviews from other countries

• Amazon Newsletter
• About Amazon
• Accessibility
• Sustainability
• Press Center
• Investor Relations
• Amazon Devices
• Amazon Science
• Sell on Amazon
• Sell apps on Amazon
• Supply to Amazon
• Protect & Build Your Brand
• Become an Affiliate
• Become a Delivery Driver
• Start a Package Delivery Business
• Advertise Your Products
• Self-Publish with Us
• Become an Amazon Hub Partner
• › See More Ways to Make Money
• Amazon Visa
• Amazon Store Card
• Amazon Secured Card
• Amazon Business Card
• Shop with Points
• Credit Card Marketplace
• Reload Your Balance
• Amazon Currency Converter
• Your Account
• Your Orders
• Shipping Rates & Policies
• Amazon Prime
• Returns & Replacements
• Manage Your Content and Devices
• Recalls and Product Safety Alerts
• Conditions of Use
• Privacy Notice
• Consumer Health Data Privacy Disclosure
• Your Ads Privacy Choices